6-硝基芦竹碱 | 6954-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-硝基芦竹碱
• 中文别名: 3-(二甲氨甲基)-6-硝基吲哚
• 英文名称: 6-nitrogramine
• 英文别名: N,N-dimethyl-1-(6-nitro-1H-indol-3-yl)methanamine
• CAS: 6954-87-6
• 化学式: C₁₁H₁₃N₃O₂
• mdl: MFCD00159849
• 分子量: 219.243
• InChiKey: PMTRDROSYRMMAD-UHFFFAOYSA-N

物化性质

• 熔点：
  178-180 °C
• 沸点：
  377.9±27.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Dimethyl[(6-nitro-1H-indol-3-yl)methyl]amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Dimethyl[(6-nitro-1H-indol-3-yl)methyl]amine
CAS number: 6954-87-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H13N3O2
Molecular weight: 219.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-硝基芦竹碱 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 5.17h， 生成 (6-氨基-吲哚-3-基)-乙腈
  参考文献：
  名称：

  Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

  摘要：

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。

  公开号：

  US20150231142A1
• 作为产物：
  描述：

  6-硝基吲哚 在 聚合甲醛 、 二甲胺 作用下， 以 溶剂黄146 为溶剂， 以87%的产率得到6-硝基芦竹碱
  参考文献：
  名称：

  MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

  摘要：

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。

  公开号：

  US20120309758A1

文献信息

• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
  申请人：NUVATION BIO INC

  公开号：WO2021003314A1

  公开（公告）日：2021-01-07

  Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供异环化合物作为CDK4或CDK6或其他CDK抑制剂。这些化合物可能作为治疗疾病的治疗剂，特别是在肿瘤学方面可能具有特殊用途。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：giraFpharma LLC

  公开号：US20190106436A1

  公开（公告）日：2019-04-11

  Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Wee1抑制剂的杂环化合物。这些化合物可能被用作治疗药物，用于治疗疾病，并且可能在肿瘤学中发挥特定作用。
• Synthesis and NMR characteristics of <i>N</i> -acetyl-4-nitro, <i>N</i> -acetyl-5-nitro, <i>N</i> -acetyl-6-nitro and <i>N</i> -acetyl-7-nitrotryptophan methyl esters
  作者：Russell R. King、Larry A. Calhoun

  DOI：10.1002/mrc.2377

  日期：2009.3

  N‐acetyl‐4‐nitrotryptophan methyl ester (2), N‐acetyl‐5‐nitrotryptophan methyl ester (3), N‐acetyl‐6‐nitrotryptophan methyl ester (4) and N‐acetyl‐7‐nitrotryptophan methyl ester (5) were synthesized through a modified malonic ester reaction of the appropriate nitrogramine analogs followed by methylation with BF3‐methanol. Assignments of the 1H and 13C NMR chemical shifts were made using a combination

  N-乙酰基-4-硝基色氨酸甲酯（2）、N-乙酰基-5-硝基色氨酸甲酯（3）、N-乙酰基-6-硝基色氨酸甲酯（4）和N-乙酰基-7-硝基色氨酸甲酯（5 ) 是通过适当的硝基甘氨酸类似物的改性丙二酸酯反应合成的，然后用 BF3-甲醇进行甲基化。1H 和 13C NMR 化学位移的分配是使用 1H-1H COSY、1H-13C HETCOR 和 1H-13C 选择性 INEPT 实验的组合进行的。版权所有 © 2008 Crown 归加拿大所有。由 John Wiley & Sons, Ltd 出版
• Discovery of IDO1 and DNA dual targeting antitumor agents
  作者：Kun Fang、Shanchao Wu、Guoqiang Dong、Ying Wu、Shuqiang Chen、Jianhe Liu、Wei Wang、Chunquan Sheng

  DOI：10.1039/c7ob02529g

  日期：——

  molecules for cancer immunotherapy is highly challenging and indoleamine 2,3-dioxygenase 1 (IDO1) represents a promising target. Inspired by the synergistic effects between IDO1 inhibitors and traditional antitumor chemotherapeutics, the first orally active dual IDO1 and DNA targeting agents were designed by the pharmacophore fusion strategy. The bifunctional hybrids exhibited enhanced IDO1 enzyme inhibitory

  用于癌症免疫疗法的小分子的开发具有很高的挑战性，吲哚胺2，3-二加氧酶1（IDO1）代表了一个有希望的目标。受IDO1抑制剂与传统抗肿瘤化学治疗药物之间协同作用的启发，通过药效基团融合策略设计了首个口服双重IDO1和DNA靶向活性剂。与IDO1抑制剂1-甲基色氨酸和DNA烷化剂美法仑相比，双功能杂种表现出增强的IDO1酶抑制活性和体外细胞毒性。在鼠LLC肿瘤模型中，双重靶向药物表现出出色的抗肿瘤功效，突出了这种新颖设计策略的优势，可提高小分子癌症免疫疗法的功效。